Mirtazapina Aurobindo (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases norepinephrine release, and by antagonizing 5‑HT2 and 5‑HT3 serotonin receptors. This dual action enhances serotonergic and noradrenergic transmission, producing antidepressant and anxiolytic effects.

The appropriate dose of Mirtazapina Aurobindo is determined by the prescribing clinician based on the patient’s condition, response, and tolerability. Dosage may be adjusted over time, and patients should follow the prescriber’s instructions without self‑adjusting.

Safety data for mirtazapine in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies any potential risk to the fetus or infant, and decisions should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mirtazapine belongs to the NaSSA class, differing from SSRIs and SNRIs by its combined noradrenergic and specific serotonergic activity. It often causes sedation and weight gain, which can be advantageous for patients with insomnia or low appetite, whereas other antidepressants may have different side‑effect profiles.

Mirtazapina Aurobindo should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, excessive heat, and direct sunlight to maintain stability and potency.

The medication is taken orally, usually once daily in the evening, with or without food. Patients should swallow the tablet whole and follow the dosing schedule prescribed by their healthcare provider.

Serious risks include agranulocytosis, severe neutropenia, Stevens‑Johnson syndrome, hyponatremia, seizures, and the emergence or worsening of suicidal thoughts, especially during the initial treatment period. Prompt medical attention is required if any of these occur.

Mirtazapina Aurobindo should be avoided in patients taking monoamine oxidase inhibitors within the past 14 days, those with known hypersensitivity to mirtazapine, and individuals with severe hepatic impairment unless dose adjustments are made. Consultation with a clinician is essential before starting therapy.